Literature DB >> 19632080

Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer.

U Zingg1, M Montani, D M Frey, S Dirnhofer, P Went, D Oertli.   

Abstract

INTRODUCTION: Data on influence of radio-chemotherapy (RCT) on tumor-infiltrating lymphocytes (TILs) is scarce and no study addressed this issue in esophageal squamous cell cancer (SCC) so far.
METHODS: Tumor specimens of 49 patients with SCC were re-evaluated with immunohistochemical staining with anti-CD3, anti-CD4, anti-CD8, anti-CD25 and anti-FOXP3 antibodies. Lymphocytes were counted in one high power field (0.189 mm(2)) at the periphery and in the centre of tumors.
RESULTS: 21 patients received preoperative RCT, 28 proceeded directly to surgery. There was no significant difference in survival between the two groups (median survival 23.2 months vs. 22.1 months, log rank test p=n.s.). Cox regression analysis showed that no variable had a significant effect on survival. The infiltrating pattern of TILs revealed higher numbers peripherally independent of the administration of RCT. There was a significant decrease in all cell numbers except CD4(+) cells in the centre of the tumors after RCT (CD3(+)p=0.005; CD8(+)p=0.02; CD25(+)p=0.01; FoxP3(+)p=0.01). There were fewer TILs in the periphery after RCT; however, this difference only reached significance in FoxP3(+) cells (p=0.01).
CONCLUSION: Neoadjuvant RCT reduced the number of TILs in esophageal SCC. This was primarily seen in the centre of tumors and suggests that the effect of RCT on immunological response is located in the centre of tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19632080     DOI: 10.1016/j.ejso.2009.07.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma.

Authors:  K Enomoto; M Sho; K Wakatsuki; T Takayama; S Matsumoto; S Nakamura; T Akahori; T Tanaka; K Migita; M Ito; Y Nakajima
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

2.  Developmental regulation of p53-dependent radiation-induced thymocyte apoptosis in mice.

Authors:  A Gentil Dit Maurin; C Lemercier; V Collin-Faure; P N Marche; E Jouvin-Marche; S M Candéias
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

3.  Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.

Authors:  Tanya Td Soeratram; Aafke Creemers; Sybren L Meijer; Onno J de Boer; Wim Vos; Gerrit Kj Hooijer; Mark I van Berge Henegouwen; Maarten Ccm Hulshof; Jacques Jghm Bergman; Ming Lei; Maarten F Bijlsma; Bauke Ylstra; Nicole Ct van Grieken; Hanneke Wm van Laarhoven
Journal:  J Pathol       Date:  2021-12-10       Impact factor: 9.883

4.  Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis.

Authors:  Xiao-Fei Zhang; Ke Pan; De-Sheng Weng; Chang-Long Chen; Qi-Jing Wang; Jing-Jing Zhao; Qiu-Zhong Pan; Qing Liu; Shan-Shan Jiang; Yong-Qiang Li; Hong-Xia Zhang; Jian-Chuan Xia
Journal:  Oncotarget       Date:  2016-05-03

5.  SIX1 overexpression predicts poor prognosis and induces radioresistance through AKT signaling in esophageal squamous cell carcinoma.

Authors:  Zheng He; Guang Li; Lingrong Tang; Yaming Li
Journal:  Onco Targets Ther       Date:  2017-02-21       Impact factor: 4.147

Review 6.  Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.

Authors:  Hugo Teixeira Farinha; Antonia Digklia; Dimitrios Schizas; Nicolas Demartines; Markus Schäfer; Styliani Mantziari
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

7.  Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study.

Authors:  Jee Youn Lee; Taeil Son; Jae-Ho Cheong; Woo Jin Hyung; Sung Hoon Noh; Choong-Bai Kim; Chung-Gyu Park; Hyoung-Il Kim
Journal:  J Gastric Cancer       Date:  2015-12-31       Impact factor: 3.720

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.